aspirin has been researched along with Hyperglycemia in 44 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Hyperglycemia: Abnormally high BLOOD GLUCOSE level.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Acute hyperglycemia-induced enhancement of platelet activation is resistant to aspirin; a NO-donating agent suppresses it." | 9.14 | Hyperglycemia-induced platelet activation in type 2 diabetes is resistant to aspirin but not to a nitric oxide-donating agent. ( Bolli, GB; Giannini, S; Gresele, P; Guglielmini, G; Lucidi, P; Marzotti, S; Minuz, P; Momi, S, 2010) |
| " The feasibility of controlling hyperglycemia in alloxan induced diabetic mice through hepatic synthesis of insulin was studied." | 7.78 | The control of hyperglycemia in alloxan treated diabetic mice through the stimulation of hepatic insulin synthesis due to the production of nitric oxide. ( Ghosh, R; Jana, P; Sinha, AK, 2012) |
| "Chronic in vivo treatment with aspirin prevented the development of hypertension and reduced insulin resistance significantly in chronically glucose-fed rats." | 7.71 | Prevention of hypertension, hyperglycemia and vascular oxidative stress by aspirin treatment in chronically glucose-fed rats. ( de Champlain, J; El Midaoui, A; Wu, R, 2002) |
| "Acute hyperglycemia-induced enhancement of platelet activation is resistant to aspirin; a NO-donating agent suppresses it." | 5.14 | Hyperglycemia-induced platelet activation in type 2 diabetes is resistant to aspirin but not to a nitric oxide-donating agent. ( Bolli, GB; Giannini, S; Gresele, P; Guglielmini, G; Lucidi, P; Marzotti, S; Minuz, P; Momi, S, 2010) |
| "It was concluded that simultaneous inhibition of the JAK-STAT and NF-κB signalling pathways with tofacitinib and aspirin respectively, could mitigate insulin resistance and hyperglycemia in T2D." | 3.91 | Inhibition of JAK-STAT and NF-κB signalling systems could be a novel therapeutic target against insulin resistance and type 2 diabetes. ( Bako, HY; Ibrahim, MA; Ibrahim, S; Isah, MS, 2019) |
| " Two subgroups of GK and Wistar control rats were injected intraperitoneally with 100 mg aspirin/kg body weight/ day for 5 weeks." | 3.81 | Enhanced Glucose Tolerance and Pancreatic Beta Cell Function by Low Dose Aspirin in Hyperglycemic Insulin-Resistant Type 2 Diabetic Goto-Kakizaki (GK) Rats. ( Adeghate, E; Amiri, L; Howarth, FC; Jayaprakash, P; John, A; Raza, H; Shafarin, J; Yasin, J, 2015) |
| " The feasibility of controlling hyperglycemia in alloxan induced diabetic mice through hepatic synthesis of insulin was studied." | 3.78 | The control of hyperglycemia in alloxan treated diabetic mice through the stimulation of hepatic insulin synthesis due to the production of nitric oxide. ( Ghosh, R; Jana, P; Sinha, AK, 2012) |
| "Since hyperglycemia is involved in the "aspirin resistance" occurring in diabetes, we aimed at evaluating whether high glucose interferes with the aspirin-induced inhibition of thromboxane synthesis and/or activation of the nitric oxide (NO)/cGMP/cGMP-dependent protein kinase (PKG) pathway in platelets." | 3.78 | High glucose inhibits the aspirin-induced activation of the nitric oxide/cGMP/cGMP-dependent protein kinase pathway and does not affect the aspirin-induced inhibition of thromboxane synthesis in human platelets. ( Anfossi, G; Barale, C; Cavalot, F; Doronzo, G; Mattiello, L; Pagliarino, A; Russo, I; Trovati, M; Viretto, M, 2012) |
| "Chronic in vivo treatment with aspirin prevented the development of hypertension and reduced insulin resistance significantly in chronically glucose-fed rats." | 3.71 | Prevention of hypertension, hyperglycemia and vascular oxidative stress by aspirin treatment in chronically glucose-fed rats. ( de Champlain, J; El Midaoui, A; Wu, R, 2002) |
| "Chronic hyperglycemia is then added to these risk markers." | 2.40 | Multifactorial aspects of the treatment of the type II diabetic patient. ( Colwell, JA, 1997) |
| "Pentamidine was frequently associated with dysglycaemia due to its pancreatic beta-cell cytotoxic effects but is now used less often to treat Pneumocystis carinii pneumonia in immunosuppressed patients." | 2.39 | Drug-induced disorders of glucose metabolism. Mechanisms and management. ( Chan, JC; Cockram, CS; Critchley, JA, 1996) |
| "Recognizing SIDS as part of the diagnostic criteria for BrS would help us identifying a significant number of families susceptible to develop SCD (as well as SIDS)." | 1.40 | EKG pattern of Brugada syndrome and sudden infant death syndrome--is it time to review the diagnostic criteria? Case report and review of literature. ( Dias, A; Franco, E; Hebert, K; Teresa, D, 2014) |
| "Dyslipidemia is associated with macular exudates and vision loss." | 1.32 | Preventing diabetic retinopathy through control of systemic factors. ( Fong, D; Jain, A; Sarraf, D, 2003) |
| "Diabetes Mellitus is a chronic disease frequently associated to ischemic heart disease and both disease require continuing medical care, aggressive treatment of other risk factors, educational programs for self management of disease to prevent acute complication." | 1.32 | [Recommendations for cardiovascular rehabilitation in diabetes mellitus]. ( Biorci, ML; Camerini, A; Chieffo, C; Comaschi, M; Faglia, E; Fattirolli, F; Gattone, M; Giorda, C; Griffo, R; Mannucci, E, 2003) |
| " A dose-response relationship was evident between incident opacities and increased levels of glycosylated hemoglobin at baseline, with the highest risk of cortical (RR = 3." | 1.32 | Risk factors for incident cortical and posterior subcapsular lens opacities in the Barbados Eye Studies. ( Hennis, A; Leske, MC; Nemesure, B; Wu, SY, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (13.64) | 18.7374 |
| 1990's | 5 (11.36) | 18.2507 |
| 2000's | 17 (38.64) | 29.6817 |
| 2010's | 11 (25.00) | 24.3611 |
| 2020's | 5 (11.36) | 2.80 |
| Authors | Studies |
|---|---|
| Mac Grory, B | 1 |
| Piccini, JP | 1 |
| Yaghi, S | 1 |
| Poli, S | 1 |
| De Havenon, A | 1 |
| Rostanski, SK | 1 |
| Weiss, M | 1 |
| Xian, Y | 1 |
| Johnston, SC | 1 |
| Feng, W | 1 |
| Hu, X | 1 |
| Liu, C | 1 |
| Zhang, M | 1 |
| Zhang, W | 1 |
| Dai, Y | 1 |
| Xu, R | 1 |
| Wu, G | 1 |
| Yin, Z | 1 |
| Zhang, H | 1 |
| Li, H | 1 |
| Chen, W | 1 |
| Bako, HY | 1 |
| Ibrahim, MA | 1 |
| Isah, MS | 1 |
| Ibrahim, S | 1 |
| Giorda, CB | 1 |
| Bonaca, MP | 1 |
| Hamburg, NM | 1 |
| Creager, MA | 1 |
| Rahmatullah, M | 2 |
| Hossain, M | 1 |
| Mahmud, A | 1 |
| Sultana, N | 1 |
| Rahman, SM | 1 |
| Islam, MR | 1 |
| Khatoon, MS | 1 |
| Jahan, S | 1 |
| Islam, F | 1 |
| Franco, E | 1 |
| Dias, A | 1 |
| Teresa, D | 1 |
| Hebert, K | 1 |
| Amiri, L | 1 |
| John, A | 1 |
| Shafarin, J | 1 |
| Adeghate, E | 1 |
| Jayaprakash, P | 1 |
| Yasin, J | 1 |
| Howarth, FC | 1 |
| Raza, H | 1 |
| Patel, A | 1 |
| Joshi, R | 1 |
| de Galan, B | 1 |
| Pulcinelli, FM | 1 |
| Biasucci, LM | 1 |
| Riondino, S | 1 |
| Giubilato, S | 1 |
| Leo, A | 1 |
| Di Renzo, L | 1 |
| Trifirò, E | 1 |
| Mattiello, T | 1 |
| Pitocco, D | 1 |
| Liuzzo, G | 1 |
| Ghirlanda, G | 1 |
| Crea, F | 1 |
| Gresele, P | 1 |
| Marzotti, S | 1 |
| Guglielmini, G | 1 |
| Momi, S | 1 |
| Giannini, S | 1 |
| Minuz, P | 1 |
| Lucidi, P | 1 |
| Bolli, GB | 1 |
| Ghosh, R | 2 |
| Karmohapatra, SK | 1 |
| Bhattacharyya, M | 1 |
| Bhattacharya, R | 1 |
| Bhattacharya, G | 1 |
| Sinha, AK | 2 |
| Yoshikawa, Y | 1 |
| Adachi, Y | 1 |
| Yasui, H | 1 |
| Hattori, M | 1 |
| Sakurai, H | 1 |
| Reza, H | 1 |
| Haq, WM | 1 |
| Das, AK | 1 |
| Rahman, S | 1 |
| Jahan, R | 1 |
| Jana, P | 1 |
| Ledwidge, MT | 1 |
| Ryan, F | 1 |
| Kerins, DM | 1 |
| O'Connell, D | 1 |
| Cefali, G | 1 |
| Harmon, S | 1 |
| Jones, M | 1 |
| Gilmer, JF | 1 |
| Russo, I | 1 |
| Viretto, M | 1 |
| Barale, C | 1 |
| Mattiello, L | 1 |
| Doronzo, G | 1 |
| Pagliarino, A | 1 |
| Cavalot, F | 1 |
| Trovati, M | 1 |
| Anfossi, G | 1 |
| Quilley, J | 1 |
| El Midaoui, A | 1 |
| Wu, R | 1 |
| de Champlain, J | 1 |
| Nattrass, M | 1 |
| PICKERING, D | 1 |
| Jain, A | 1 |
| Sarraf, D | 1 |
| Fong, D | 1 |
| Camerini, A | 1 |
| Chieffo, C | 1 |
| Griffo, R | 1 |
| Comaschi, M | 1 |
| Gattone, M | 1 |
| Mannucci, E | 1 |
| Faglia, E | 1 |
| Giorda, C | 1 |
| Biorci, ML | 1 |
| Fattirolli, F | 1 |
| Hennis, A | 1 |
| Wu, SY | 1 |
| Nemesure, B | 1 |
| Leske, MC | 1 |
| Watala, C | 2 |
| Pluta, J | 1 |
| Golanski, J | 2 |
| Rozalski, M | 1 |
| Czyz, M | 1 |
| Trojanowski, Z | 1 |
| Drzewoski, J | 2 |
| Ulicna, O | 1 |
| Nocun, M | 1 |
| Waczulíková, I | 1 |
| Markuszewski, L | 1 |
| Sigal, R | 1 |
| Malcolm, J | 1 |
| Arnaout, A | 1 |
| Kotake, H | 1 |
| Oikawa, S | 1 |
| Berry, C | 1 |
| Tardif, JC | 1 |
| Bourassa, MG | 1 |
| Faraday, N | 1 |
| Yanek, LR | 1 |
| Mathias, R | 1 |
| Herrera-Galeano, JE | 1 |
| Vaidya, D | 1 |
| Moy, TF | 1 |
| Fallin, MD | 1 |
| Wilson, AF | 1 |
| Bray, PF | 1 |
| Becker, LC | 1 |
| Becker, DM | 1 |
| Hynes, AM | 1 |
| Rouvinen-Watt, K | 1 |
| Kubow, S | 1 |
| Yaylayan, V | 1 |
| Mandeville, S | 1 |
| Colwell, JA | 2 |
| Chan, JC | 1 |
| Cockram, CS | 1 |
| Critchley, JA | 1 |
| Piscione, F | 1 |
| Barbato, E | 1 |
| Galasso, G | 1 |
| Chiariello, M | 1 |
| Syvänne, M | 1 |
| Pieper, GM | 1 |
| Siebeneich, W | 1 |
| Olds, CL | 1 |
| Felix, CC | 1 |
| Del Soldato, P | 1 |
| Jones, RL | 1 |
| Peterson, CM | 1 |
| Buchanan, N | 1 |
| Boquist, L | 1 |
| Bratusch-Marrain, PR | 1 |
| Vierhapper, H | 1 |
| Komjati, M | 1 |
| Waldhäusl, WK | 1 |
| Mandell, F | 1 |
| Fellers, FX | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial[NCT00991029] | Phase 3 | 4,881 participants (Actual) | Interventional | 2010-05-28 | Terminated (stopped due to The trial was halted by the DSMB.) | ||
| Effects of Pulsatile IV Insulin Delivery on Diabetic Retinopathy[NCT00287651] | Phase 2/Phase 3 | 150 participants (Actual) | Interventional | 2005-11-30 | Terminated (stopped due to Administrative) | ||
| Prevalence of Aspirin Resistance in Ischemic Stroke Patients at Assiut University Hospital[NCT05151263] | 133 participants (Anticipated) | Observational | 2023-11-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Secondary efficacy outcome: Number of participants with ischemic stroke, myocardial infarction, death from ischemic vascular causes, or major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 141 |
| Placebo | 167 |
Primary efficacy outcome: Number of Participants with Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 121 |
| Placebo | 160 |
Other safety outcome: Number of Participants with Death from any cause (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 18 |
| Placebo | 12 |
Secondary efficacy outcome: Number of participants with Death from ischemic vascular causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 6 |
| Placebo | 4 |
Other safety outcome: Number of participants with Hemorrhagic stroke (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 5 |
| Placebo | 3 |
Secondary efficacy outcome: Number of participants with Ischemic or hemorrhagic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 116 |
| Placebo | 156 |
Secondary efficacy outcome:Number of participants with Ischemic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 112 |
| Placebo | 155 |
Primary safety outcome: Number of Participants with major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 23 |
| Placebo | 10 |
Other safety outcome: Number of Participants with Major hemorrhage other than intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 17 |
| Placebo | 7 |
Other safety outcome:Number of Participants with Minor hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 40 |
| Placebo | 13 |
Secondary efficacy outcome: Number of participants with Myocardial infarction (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 10 |
| Placebo | 7 |
Other safety outcome: Number of participants with other symptomatic intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 0 |
Other safety outcome: Number of participants with Symptomatic intracerebral hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 2 |
9 reviews available for aspirin and Hyperglycemia
| Article | Year |
|---|---|
Contemporary Medical Management of Peripheral Artery Disease.
Topics: Aspirin; Atherosclerosis; Cardiovascular Diseases; Chronic Limb-Threatening Ischemia; Exercise; Fibr | 2021 |
Trials of cardiovascular risk factor management in type 2 diabetes.
Topics: Aspirin; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes | 2009 |
Prevention of cardiovascular events in diabetes.
Topics: Angioplasty, Balloon; Antihypertensive Agents; Aspirin; Bezafibrate; Cardiovascular Diseases; Clopid | 2006 |
[Guidelines for the management of atherosclerotic diseases in diabetes mellitus].
Topics: Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Complications; Dyslipidemias; Humans; Hy | 2006 |
Coronary heart disease in patients with diabetes: part I: recent advances in prevention and noninvasive management.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Coronary Disease; Diabetes | 2007 |
Drug-induced disorders of glucose metabolism. Mechanisms and management.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Angiotensin-Converti | 1996 |
Multifactorial aspects of the treatment of the type II diabetic patient.
Topics: Arteriosclerosis; Aspirin; Cardiovascular Diseases; Cardiovascular Physiological Phenomena; Diabetes | 1997 |
[Diabetes and ischemic cardiopathy].
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Diabetic Angiopathies; Hu | 2001 |
[Treatment of coronary artery disease in a patient with adult-onset diabetes mellitus].
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitor | 1999 |
4 trials available for aspirin and Hyperglycemia
| Article | Year |
|---|---|
Hyperglycemia-induced platelet activation in type 2 diabetes is resistant to aspirin but not to a nitric oxide-donating agent.
Topics: Adolescent; Adult; Aged; Aspirin; Female; Flow Cytometry; Humans; Hyperglycemia; Male; Middle Aged; | 2010 |
Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin.
Topics: Acetylation; Adult; Aspirin; Blood Platelets; Collagen; Diabetes Mellitus, Type 2; Epinephrine; Fema | 2005 |
Monitoring blood glucose levels in female mink during the reproductive cycle: 2. Effects of short-term fish oil, chromium picolinate, and acetylsalicylic acid supplementation during late lactation.
Topics: Animal Nutritional Physiological Phenomena; Animals; Aspirin; Blood Glucose; Dietary Supplements; Dr | 2007 |
Intensive insulin therapy in type II diabetes: rationale and collaborative clinical trial results.
Topics: Arteriosclerosis; Aspirin; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Res | 1996 |
31 other studies available for aspirin and Hyperglycemia
| Article | Year |
|---|---|
Hyperglycemia, Risk of Subsequent Stroke, and Efficacy of Dual Antiplatelet Therapy: A Post Hoc Analysis of the POINT Trial.
Topics: Aspirin; Blood Glucose; Clopidogrel; Humans; Hyperglycemia; Ischemic Attack, Transient; Ischemic Str | 2022 |
Impact of the
Topics: Adenosine Diphosphate; Aspirin; Cardiovascular Diseases; China; Clopidogrel; Humans; Hyperglycemia; | 2022 |
Aspirin Suppresses Hepatic Glucagon Signaling Through Decreasing Production of Thromboxane A2.
Topics: Aspirin; Diabetes Mellitus; Glucagon; Gluconeogenesis; Glucose; Humans; Hyperglycemia; Hypoglycemic | 2023 |
Inhibition of JAK-STAT and NF-κB signalling systems could be a novel therapeutic target against insulin resistance and type 2 diabetes.
Topics: Animals; Aspirin; Blood Glucose; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type | 2019 |
[2019 ESC Guidelines on diabetes, pre-diabetes and cardiovascular diseases: what's new? The diabetologist's point of view].
Topics: Anticoagulants; Aspirin; Cardiology; Cholesterol, LDL; Diabetic Cardiomyopathies; Europe; Heart Dise | 2020 |
Antihyperglycemic and antinociceptive activity evaluation of 'khoyer' prepared from boiling the wood of Acacia catechu in water.
Topics: Acacia; Acetic Acid; Analgesics; Animals; Aspirin; Bangladesh; Behavior, Animal; Blood Glucose; Diab | 2013 |
EKG pattern of Brugada syndrome and sudden infant death syndrome--is it time to review the diagnostic criteria? Case report and review of literature.
Topics: Acidosis; Adult; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brugada S | 2014 |
Enhanced Glucose Tolerance and Pancreatic Beta Cell Function by Low Dose Aspirin in Hyperglycemic Insulin-Resistant Type 2 Diabetic Goto-Kakizaki (GK) Rats.
Topics: Animals; Aspirin; Body Weight; Diabetes Mellitus, Type 2; Dinoprostone; Dose-Response Relationship, | 2015 |
COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment.
Topics: Adult; Aged; Aspirin; Blood Platelets; C-Reactive Protein; Case-Control Studies; Cyclooxygenase 1; D | 2009 |
The appearance of dermcidin isoform 2, a novel platelet aggregating agent in the circulation in acute myocardial infarction that inhibits insulin synthesis and the restoration by acetyl salicylic acid of its effects.
Topics: Animals; Aspirin; Coagulants; Female; Humans; Hyperglycemia; Insulin; Insulin-Secreting Cells; Male; | 2011 |
Oral administration of Bis(aspirinato)zinc(II) complex ameliorates hyperglycemia and metabolic syndrome-like disorders in spontaneously diabetic KK-A(y) mice: structure-activity relationship on zinc-salicylate complexes.
Topics: Adiponectin; Administration, Oral; Animals; Aspirin; Blood Pressure; Coordination Complexes; Diabete | 2011 |
Anti-hyperglycemic and antinociceptive activity of methanol leaf and stem extract of Nypa fruticans Wurmb.
Topics: Acetic Acid; Analgesics; Animals; Arecaceae; Aspirin; Blood Glucose; Glucose; Glyburide; Hyperglycem | 2011 |
The control of hyperglycemia in alloxan treated diabetic mice through the stimulation of hepatic insulin synthesis due to the production of nitric oxide.
Topics: Administration, Cutaneous; Administration, Oral; Alloxan; Animals; Anti-Inflammatory Agents, Non-Ste | 2012 |
In vivo impact of prodrug isosorbide-5-nicotinate-2-aspirinate on lipids and prostaglandin D2: is this a new immediate-release therapeutic option for niacin?
Topics: Animals; Apolipoproteins B; Aspirin; Blood Glucose; Chemistry, Pharmaceutical; Cholesterol, LDL; Cyc | 2012 |
High glucose inhibits the aspirin-induced activation of the nitric oxide/cGMP/cGMP-dependent protein kinase pathway and does not affect the aspirin-induced inhibition of thromboxane synthesis in human platelets.
Topics: Adult; Amifostine; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Cell Adhesion | 2012 |
Insulin resistance, oxidative stress and aspirin: therapeutic implications?
Topics: Animals; Aspirin; Cyclooxygenase Inhibitors; Glucose; Humans; Hyperglycemia; Hypertension; Insulin R | 2002 |
Prevention of hypertension, hyperglycemia and vascular oxidative stress by aspirin treatment in chronically glucose-fed rats.
Topics: Animals; Aorta; Aspirin; Blood Glucose; Blood Pressure; Body Weight; Canada; Cyclooxygenase Inhibito | 2002 |
Management of hyperglycaemia in the patient with acute myocardial infarction.
Topics: Aspirin; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Metformin; | 2003 |
SALICYLATE POISONING: THE DIAGNOSIS WHEN ITS POSSIBILITY IS DENIED BY THE PARENTS.
Topics: Aspirin; Child; Coma; Diabetic Coma; Diagnosis; Diagnosis, Differential; Humans; Hyperglycemia; Infa | 1964 |
Preventing diabetic retinopathy through control of systemic factors.
Topics: Anticoagulants; Aspirin; Diabetic Angiopathies; Diabetic Retinopathy; Disease Progression; Female; G | 2003 |
[Recommendations for cardiovascular rehabilitation in diabetes mellitus].
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Angioplasty, Balloon; Aspirin; Blood Glucose; Cardiov | 2003 |
Risk factors for incident cortical and posterior subcapsular lens opacities in the Barbados Eye Studies.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Barbados; Black People; Cataract; Cohort Studies; Diabetes | 2004 |
High glucose contributes to aspirin insensitivity in streptozotocin-diabetic rats: a multiparametric aggregation study.
Topics: Animals; Aspirin; Blood Glucose; Blood Platelets; Chronic Disease; Diabetes Mellitus, Experimental; | 2006 |
Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1.
Topics: Adult; Arachidonic Acid; Aspirin; beta-Thromboglobulin; Black or African American; Blood Platelets; | 2007 |
Protection by acetylsalicylic acid against hyperglycemia-induced glycation and neural tube defects in cultured early somite mouse embryos.
Topics: Animals; Aspirin; Embryo, Mammalian; Female; Glucose; Glycosylation; Hyperglycemia; Male; Mice; Mice | 1993 |
Vascular protective actions of a nitric oxide aspirin analog in both in vitro and in vivo models of diabetes mellitus.
Topics: Acetylcholine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aorta, Thoracic; Aspirin; Diabetes | 2002 |
Reduced fibrinogen survival in diabetes mellitus. A reversible phenomenon.
Topics: Adult; Aged; Aspirin; Chromatography, DEAE-Cellulose; Chromatography, Gel; Diabetes Mellitus; Dipyri | 1979 |
Salicylate intoxication in infancy: a review.
Topics: Acidosis; Alkalosis; Alkalosis, Respiratory; Animals; Aspirin; Child; Child, Preschool; Dehydration; | 1975 |
Inhibition by acetylsalicylate of the hyperglycemic response induced in mice by sodium nitroprusside.
Topics: Animals; Aspirin; Blood Glucose; Female; Ferricyanides; Glutamate Dehydrogenase; Hyperglycemia; Insu | 1989 |
Acetyl-salicylic acid impairs insulin-mediated glucose utilization and reduces insulin clearance in healthy and non-insulin-dependent diabetic man.
Topics: Adult; Aspirin; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Humans; Hyperglycemia; | 1985 |
Hyperglycemia in hypernatremic dehydration.
Topics: Antigens; Aspirin; Blood; Blood Glucose; Blood Urea Nitrogen; Child; Child, Preschool; Chlorides; De | 1974 |